Inhibition of GCPII activity has demonstrated benefit in a host of preclinical studies, including models of schizophrenia, Alzheimer's disease, ethanol intoxication, and pain 51, 52, in addition to MS 8, 9. Here, FOLH1 is linked to schizophrenia.